Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Evotec SE

A Comparative Analysis of SG&A Expenses: Teva vs. Evotec

In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Teva Pharmaceutical Industries Limited and Evotec SE, from 2014 to 2023. Over this period, Teva's SG&A expenses have shown a downward trend, decreasing by approximately 32%, from 5.08 billion to 3.50 billion. In contrast, Evotec's expenses have surged by nearly 843%, reflecting its aggressive expansion strategy. This divergence highlights Teva's focus on cost optimization, while Evotec invests heavily in growth. The data underscores the strategic choices each company makes in response to market dynamics, offering valuable insights for investors and industry analysts alike. As the pharmaceutical landscape continues to shift, understanding these financial strategies becomes crucial for stakeholders.